{"id":11130,"date":"2018-04-03T13:41:23","date_gmt":"2018-04-03T11:41:23","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=11130"},"modified":"2021-03-12T10:40:17","modified_gmt":"2021-03-12T09:40:17","slug":"bioinvent-international-ab-has-carried-out-a-directed-issue-of-approximately-sek-85-million","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/en\/assignment\/bioinvent-international-ab-has-carried-out-a-directed-issue-of-approximately-sek-85-million\/","title":{"rendered":"BioInvent International AB has carried out a directed issue of approximately SEK 85 million"},"content":{"rendered":"<p>BioInvent International has carried out a directed issue raising approximately SEK 85 million through an accelerated book building process.<\/p>\n<p>BioInvent International AB is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The company has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. BioInvent International&#8217;s shares are listed on Nasdaq Stockholm.<\/p>\n<p>BioInvent International was advised by Mannheimer Swartling in the transaction.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioInvent International has carried out a directed issue raising approximately SEK 85 million through an accelerated book building process. BioInvent International AB is focused on\u2026<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4313],"tags":[],"class_list":["post-11130","post","type-post","status-publish","format-standard","hentry","category-assignment","business-group-public-ma-and-equity-capital-markets"],"acf":[],"lang":"en","translations":{"en":11130,"sv":11128},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/11130"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=11130"}],"version-history":[{"count":2,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/11130\/revisions"}],"predecessor-version":[{"id":14866,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/11130\/revisions\/14866"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=11130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=11130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=11130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}